v3.25.2
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
May 31, 2025
Dec. 31, 2024
May 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities              
Net loss $ (449,295) $ (2,658,887)   $ (4,157,737)   $ (4,340,975) $ (11,525,102)
Amortization and depreciation       255,046   1,125,254 1,207,510
Share-based compensation         1,265,189 1,646,999
Loss on investments in marketable securities, net         9,266 134,134
Unrealized gain from fair value change of the long-term investments, net         (6,431,088) (6,108,872)
Impairment loss of long-term investment       1,000,000   77,200 520,821
Gain on disposal of fixed assets       (58,621)   110,852 205,189
Impairment loss on long-lived assets       1,699,481   750,381
Allowance for credit loss of due from a related party         521,007
Write-off of prepayment and other receivables       45,677   62,369
Write-off of accounts receivable       6,280  
Write-down of inventories         13,206
Gain on disposal of subsidiaries 4,271   (703)  
Amortization of right-of-use assets       50,520   252,345 349,031
Interest income         (235,560)
Interest expense and accretion of convertible debts       180,000   45,266 87,537
Accretion of finance lease obligation         1,435
Reversal of deferred cash bonus         (1,646,228)
Adjustments to reconcile net loss to net cash used in operating activities              
Amortization and depreciation       255,046   1,125,254 1,207,510
Share-based compensation         1,265,189 1,646,999
Loss on investments in marketable securities, net         9,266 134,134
Unrealized gain from fair value change of the long-term investments, net         (6,431,088) (6,108,872)
Impairment loss of long-term investment       1,000,000   77,200 520,821
Gain on disposal of fixed assets       (58,621)   110,852 205,189
Impairment loss on long-lived assets       1,699,481   750,381
Allowance for credit loss of due from a related party         521,007
Write-off of prepayment and other receivables       45,677   62,369
Write-off of accounts receivable       6,280  
Write-down of inventories         13,206
Gain on disposal of subsidiaries 4,271   (703)  
Amortization of right-of-use assets       50,520   252,345 349,031
Interest income         (235,560)
Interest expense and accretion of convertible debts       180,000   45,266 87,537
Accretion of finance lease obligation         1,435
Reversal of deferred cash bonus         (1,646,228)
Changes in operating assets and liabilities              
Accounts receivable       41,349   126,717 (95,704)
Inventories         14,516 8,053
Other receivables and prepayments       291,078   227,457 (29,856)
Long-term deposits         29,106 19,328
Amounts due from related parties       961   63,050 (46,349)
Amounts due to related parties       464   (8,524) (6,805)
Accounts payable and accrued expenses       (422,705)   398,635 1,918,751
Operating lease liabilities       (120,824)   (389,365) (369,505)
Net cash used in operating activities (816,544) (1,280,887)   (1,189,734)   (7,724,364) (12,318,965)
Cash flows from investing activities              
Purchases of property and equipment         (3,015) (186,916)
Proceeds from disposal of property and equipment       58,621   15,385
Disposal of subsidiaries, net of cash disposed          
Proceeds from sales of investment securities         93,215
Loan to a related party         (92,459) (330,341)
Repayment of loan and interest from a related party         611,641 2,962,153
Net cash provided by investing activities 58,621   58,621   624,767 2,444,896
Cash flows from financing activities              
Loan from related parties         2,500,000 500,000
Proceeds from issuance of subsidiaries shares         5,360
Proceeds from issuance of Class A Ordinary Shares and warrants         1,575,562
Exercise of share options         16,506 169,460
Loan from a bank         3,000,000
Repayment of bank loan         (3,000,000)
Proceeds from issuance of convertible notes         3,000,000 3,000,000
Payment of finance lease obligations         (49,358)
Proceeds from issuance of Class A Ordinary Shares, net 3,070,000          
Payment of offering cost (370,800)            
Net cash provided by financing activities 2,699,200     4,092,068 6,625,462
Net decrease in cash and restricted cash 1,882,656 (1,222,266)   (1,131,113)   (3,007,529) (3,248,607)
Cash and restricted cash – Beginning of period 874,238 2,005,351   2,005,351   5,012,880 8,261,487
Cash and restricted cash – End of period 2,756,894 783,085   874,238   2,005,351 5,012,880
Supplemental disclosures of cash flow information              
Interest paid     94,108 64,744
Income taxes paid    
Non-cash operating, investing and financing activities              
Right-of-use assets obtained in exchange for new operating lease liabilities         338,525 549,596
Convertible notes converted to Class A Ordinary Shares       6,000,000
Settlement of deferred cash bonus by issuance of share options or shares $ 451,660   451,660   3,078,196
Reconciliation of cash and restricted cash              
Cash and cash equivalents       874,238   2,005,351 1,882,545
Restricted cash         3,130,335
Total cash and restricted cash shown on the unaudited condensed consolidated statements of cash flows       $ 874,238   $ 2,005,351 $ 5,012,880
DiamiR Biosciences Corp              
Cash flows from operating activities              
Net loss     $ (743,235)   $ (614,405)    
Depreciation expense     20,828   20,052    
Amortization and depreciation     20,828   20,052    
Deferred offering costs expensed     150,526      
Share-based compensation     24,312   194,846    
Noncash lease expense     (1,830)   (8,450)    
Amortization of note discount     43,538   25,367    
Adjustments to reconcile net loss to net cash used in operating activities              
Depreciation expense     20,828   20,052    
Amortization and depreciation     20,828   20,052    
Deferred offering costs expensed     150,526      
Share-based compensation     24,312   194,846    
Noncash lease expense     (1,830)   (8,450)    
Amortization of note discount     43,538   25,367    
Changes in operating assets and liabilities              
Accounts receivable     89,281   (89,281)    
Prepaid expenses     (77,036)   (89,334)    
Accounts payable and accrued expenses     83,210   108,997    
Accrued interest     34,634   23,232    
Deferred revenue     43,982      
Income taxes payable     16,483   112,947    
Operating lease liabilities     1,867   7,115    
Net cash used in operating activities     (313,440)   (308,914)    
Cash flows from investing activities              
Purchases of property and equipment       (1,278)    
Net cash provided by investing activities       (1,278)    
Cash flows from financing activities              
Proceeds from notes payable to founder     300,000   200,000    
Net cash provided by financing activities     300,000   200,000    
Net decrease in cash and restricted cash     (13,440)   (110,192)    
Cash and restricted cash – Beginning of period     70,276   180,468    
Cash and restricted cash – End of period     56,836   70,276    
Non-cash investing and financing activities:              
Discounts on note payable to founder     34,692   35,063    
Supplemental disclosures of cash flow information              
Interest paid          
Income taxes paid     1,456   1,456    
Reconciliation of cash and restricted cash              
Cash and cash equivalents